Unicycive Therapeutics, Inc. Annual Share-based Payment Arrangement, Expense in USD from 2020 to 2023

Taxonomy & unit
us-gaap: USD
Description
Amount of expense for award under share-based payment arrangement. Excludes amount capitalized.
Summary
Unicycive Therapeutics, Inc. quarterly/annual Share-based Payment Arrangement, Expense history and growth rate from 2020 to 2023.
  • Unicycive Therapeutics, Inc. Share-based Payment Arrangement, Expense for the quarter ending September 30, 2024 was $605K, a 34.9% decline year-over-year.
  • Unicycive Therapeutics, Inc. Share-based Payment Arrangement, Expense for the twelve months ending September 30, 2024 was $2.32M.
  • Unicycive Therapeutics, Inc. annual Share-based Payment Arrangement, Expense for 2023 was $1.77M, a 68.8% increase from 2022.
  • Unicycive Therapeutics, Inc. annual Share-based Payment Arrangement, Expense for 2022 was $1.05M, a 8.39% increase from 2021.
  • Unicycive Therapeutics, Inc. annual Share-based Payment Arrangement, Expense for 2021 was $966K, a 316% increase from 2020.
Share-based Payment Arrangement, Expense, Trailing 12 Months (USD)
Share-based Payment Arrangement, Expense, Annual (USD)
Share-based Payment Arrangement, Expense, YoY Annual Growth (%)
Period Value YoY Chg Change % Start Date End Date Report Filed
2023 $1.77M +$720K +68.8% Jan 1, 2023 Dec 31, 2023 10-K 2024-03-28
2022 $1.05M +$81K +8.39% Jan 1, 2022 Dec 31, 2022 10-K 2024-03-28
2021 $966K +$734K +316% Jan 1, 2021 Dec 31, 2021 10-K 2023-03-31
2020 $232K Jan 1, 2020 Dec 31, 2020 10-K 2022-03-31
* An asterisk sign (*) next to the value indicates that the value is likely invalid.